6 Cancer Drugs FDA Approved in August 2026 and What They Mean for You

August 2026 brought six approvals from the Food and Drug Administration spanning pancreatic cancer, gastroesophageal cancer, multiple myeloma, melanoma and two rare blood disorders. Here is what each approval means for patients.

1. Rasonque for Metastatic Pancreatic Cancer

Approved: Aug. 26 | Read more

Rasonque (daraxonrasib), a first-in-class oral RAS inhibitor, was approved for adults with metastatic pancreatic adenocarcinoma after at least one prior therapy or who cannot receive multiagent chemotherapy.

What it means: RAS mutations drive most pancreatic cancers and were long considered undruggable. In the RASolute 302 trial, people on Rasonque lived a median of 13.2 months versus 6.7 months on chemotherapy, cutting the risk of death by roughly 60%. Progression-free survival doubled, from 3.6 to 7.2 months, and only 1.2% stopped treatment for side effects versus 11.2% on chemotherapy. For a disease where gains are usually measured in weeks, this is a landmark.

Side effects: rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, swelling, decreased appetite, bleeding.

2. Ziihera Combinations for HER2-Positive Gastroesophageal Cancer

Approved: Aug. 25 | Read more

Ziihera (zanidatamab-hrii) was approved as first-line treatment for advanced HER2-positive cancers of the stomach, gastroesophageal junction and esophagus, either with Tevimbra (tislelizumab-jsgr) and chemotherapy, or with chemotherapy alone for strongly HER2-positive disease.

What it means: Ziihera is a bispecific antibody that binds HER2 in two places, stripping it from cancer cells and activating the immune system. In the phase 3 HERIZON-GEA-01 trial, Ziihera regimens delayed progression to a median of 12.4 months versus 8.1 months with trastuzumab and chemotherapy, and the three-drug combination extended median overall survival to 26.4 months versus 19.2 months. This sets a new first-line standard.

Side effects: diarrhea (85%; severe in 24%, with a boxed warning), nausea, decreased appetite, vomiting, low potassium, fatigue, rash, peripheral neuropathy, infusion reactions, reduced heart function, fetal harm (boxed warning).

3. Zenbexus Combination for Relapsed Multiple Myeloma

Approved: Aug. 13 (accelerated) | Read more

Zenbexus (iberdomide), a once-daily pill, was approved with subcutaneous daratumumab and hyaluronidase-fihj and dexamethasone for adults with myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent.

What it means: In the EXCALIBER-RRMM trial, 41% of people on the Zenbexus combination reached minimal residual disease-negative complete response, meaning no detectable myeloma cells, versus 21% on daratumumab, bortezomib and dexamethasone. Continued approval may depend on confirming a survival benefit. Zenbexus is available only through a REMS program because of fetal risk.

Side effects: embryo-fetal toxicity and serious blood clots (boxed warnings), neutropenia, infections, second primary cancers.

4. Tudriqev Plus Opdivo for Advanced Melanoma

Approved: Aug. 6 (accelerated) | Read more

Tudriqev (vusolimogene oderparepvec-wtpg), an oncolytic virus injected into tumors, was approved with Opdivo (nivolumab) for adults with unresectable advanced cutaneous melanoma that progressed after PD-1 immunotherapy.

What it means: Melanoma that stops responding to PD-1 drugs has had few options. Tudriqev is an engineered herpes virus that bursts melanoma cells and alerts the immune system; Opdivo sustains the attack. In the IGNYTE trial, 24.2% of evaluable patients responded, with responses lasting a median of 14.1 months and some still ongoing.

Side effects: accidental viral exposure, herpes infection or reactivation, injection-site complications, immune-related side effects.

5. Mimrylo for Polycythemia Vera

Approved: Aug. 28 | Read more

Mimrylo (rusfertide), a once-weekly injection, was approved for adults with polycythemia vera, a rare blood cancer that causes too many red blood cells.

What it means: Many patients rely on repeated phlebotomy to keep hematocrit below 45%. Mimrylo, the first hepcidin mimetic, limits the iron available for red blood cell production. In the phase 3 VERIFY trial, 76.9% of people on Mimrylo went without phlebotomy between weeks 20 and 32, versus 32.9% on placebo.

Side effects: injection site reactions, anemia.

6. Besremi for Essential Thrombocythemia

Approved: Aug. 31 | Read more

Besremi (ropeginterferon alfa-2b-njft), already approved for polycythemia vera, gained a new indication for adults with essential thrombocythemia, including those newly diagnosed and untreated.

What it means: Essential thrombocythemia drives platelet overproduction and raises clot risk. Besremi, a long-acting interferon, targets disease-driving cells in the bone marrow. In the phase 3 SURPASS-ET trial, it produced more durable responses than anagrelide and reduced clotting events over 12 months. It carries a boxed warning and is not appropriate for people with a history of severe depression or active autoimmune disease.

Side effects: neuropsychiatric, autoimmune, ischemic and infectious disorders (boxed warning), depression, low blood counts, cardiovascular toxicity, elevated triglycerides, liver and kidney toxicity.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.